Navigation Links
Bionovo Announces Presentation at the National Cancer Institute
Date:2/4/2009

EMERYVILLE, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced that company researchers will be presenting at the National Cancer Institute's Office of Cancer Complementary and Alternative Medicine's (OCCAM) monthly lecture series. The title of the presentation is "Selective Cytotoxic Activity of BZL 101 Towards Cancer Cells and Anti-Tumor Effects in Patients with Advanced Breast Cancer," and will be presented by Dr. Emma Shtivelman, Bionovo's Director of Cancer Research, and Dr. Mary Tagliaferri, Bionovo's President and Chief Medical Officer.

Dr. Emma Shtivelman earned her Ph.D. in molecular biology from the Weizmann Institute of Science, Israel. She was a postdoctoral associate at the G.W. Hooper Research Foundation University of California, San Francisco. She is the recipient of several awards including J. F. Kennedy Prize of Excellence and the Israeli Parliament Award for Excellence in Studies. Dr. Shtivelman has patents resulting from her work.

Dr. Mary Tagliaferri, a graduate from Cornell University, received her medical degree from the University of California, San Francisco. She also holds a master's degree in Traditional Chinese Medicine from the American College of Traditional Chinese Medicine.

Dr. Tagliaferri has over 13 years experience in translational research with the University of California, San Francisco and Bionovo, Inc. Dr. Tagliaferri has spearheaded multiple scientific R & D projects to develop pharmaceutical agents for indications in women's health and cancer. As one of the co-founders of Bionovo Inc, she has extensive experience with FDA regulatory affairs, and she has successfully filed a number of Investigational New Drug Licenses (INDs). She has been involved in all aspects of drug development, from preclinical testing to developing FDA approved protocols for clinical trials. As the chief medical officer of Bionovo, she currently manages and directs the daily activities of all clinical research projects being conducted at prestigious medical centers throughout the United States and abroad.

The lecture is scheduled to take place on Wednesday, February 4, 2009 from 3:00-4:00 PM EST at Executive Plaza North, 6130 Executive Blvd, Conference Room H, Bethesda, MD 20892. The lecture is open to the public and a webcast will become available a few weeks after the date of the lecture at: http://www.cancer.gov/cam/news/monthly-lecture-series-2009.html

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The Company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and BZL101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bionovo Announces Cost Control Measures Taken
2. Willa A. Hsueh, M.D., Joins Bionovos Scientific Advisory Board
3. Bionovo to Present Recent Findings of BN108, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
4. Bionovo to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
5. John D. Baxter, M.D. Joins Bionovos Board of Directors
6. Bionovo to Present at the Cambria Capital Investor Meeting
7. Bionovo Announces 2007 Financial Results and Highlights
8. Bionovo Describes a New Class of Therapeutic Compounds
9. Bionovo Announces Closing of Public Offering of Common Stock
10. Kensey Nash Announces Director Resignation
11. USP announces new standards to protect patients from counterfeit and adulterated medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... For over twenty-four years, Doctors on Liens has published a directory ... high quality medical care. When the company started in 1997, the directory was a ... day and the now ten-page directory features a vast array of medical specialists ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of the print ... to practice medicine at an early age by his father, who was also a ... prescribing medicine,” he states. “It is about building relationships with people; relationships that are ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” hits ... proof that attitude and determination can combine into the most remarkable achievements. Over ... holidays. This campaign will offer patients a new-found hope, by seizing the opportunity ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 According to a ... by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical ... Nephrology, Infectious Diseases) - Forecast to 2021" published ... USD 60.22 Billion in 2016. This market is ... during the forecast period (2016-2021) to reach USD ...
(Date:12/2/2016)... 2, 2016  The Addiction Treatment Advisory Group ... Managed Care Pharmacy (AMCP), has released detailed findings ... the opioid addiction crisis, including through improved access ... ATAG,s newly released paper, "The Role of ... addresses many issues around gaps and barriers to ...
(Date:12/2/2016)... 2016 Boston Scientific Corporation (NYSE: ... certain manufacturing assets and capabilities of the Neovasc, Inc., ... tissue business, as well as a 15% equity stake ... cash. The Neovasc advanced biological tissue business makes elements ... Lotus™ Valve System. * Upon completion of the ...
Breaking Medicine Technology: